Exagamglogene autotemcel
Casgevy (exagamglogene autotemcel) is a gene pharmaceutical. Exagamglogene autotemcel was first approved as Casgevy on 2023-12-08. It is used to treat sickle cell anemia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Casgevy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Exagamglogene autotemcel
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Casgevy | Exagamglogene autotemcel | Vertex Pharmaceuticals | N-125787 RX | 2023-12-08 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| casgevy | Biologic Licensing Application | 2025-08-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sickle cell anemia | EFO_0000697 | D000755 | D57 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
exagamglogene autotemcel, Casgevy, Vertex Pharmaceuticals Inc | |||
| 2031-01-16 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 2 | 6 | — | — | 6 |
| Hemoglobinopathies | D006453 | — | D58.2 | — | 2 | 6 | — | — | 6 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | 5 | — | — | 5 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | 1 | 4 | — | — | 4 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | 4 | — | — | 4 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | 1 | 4 | — | — | 4 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Exagamglogene autotemcel |
| INN | exagamglogene autotemcel |
| Description | Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
|
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL5095474 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15572 |
| UNII ID | S53L777GM8 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Casgevy – Vertex Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use